Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma

Phase 2 Completed 19 enrolled Asan Medical Center Schering-Plough · collab

NaSingle-groupOpen-labelTreatment

Summary

In order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning regimen. Investigators expect this radioimmunotherapy of Zevalin plus busulfan, cyclophosphamide and etoposide regimen will improve survival of relapsed or poor-risk B-cell non-Hodgkin's lymphoma.

Timeline

Start: 2005-11
Primary completion: 2009-02
Completion: 2010-05

Publications

Results Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest New Drugs. 2010 Aug;28(4):516-22. doi: 10.1007/s10637-009-9283-z. Epub 2009 Jun 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	90Y-ibritumomab tiuxetan	Other / unclassified	0.4 mbq/kg	Intravenous
Background	Busulfan	Small molecule	0.8 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	50 mg/kg	Intravenous
Background	Etoposide	Small molecule	200 mg/m2	Intravenous
Background	Rituximab	Monoclonal antibody	250 mg/m2	Intravenous

Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications